3/14/23 08:30 | 3/10/23 | ORTX | Health | BioPrd | Biological Products, (No Diag | Thomas Frank E | X0 | O | See Rema | M.d | 9 | 0.4591 | 0 | 20 | 28 | 92 | D | | | | | | | | | | | | | | |
2/13/23 08:09 | 2/9/23 | ORTX | Health | BioPrd | Biological Products, (No Diag | Thomas Frank E | X0 | O | See Rema | M.d | 9 | 0.4591 | 0 | 20 | 38 | 72 | D | | | | | | | | | | | | | | |
4/5/22 16:15 | 4/1/22 | ORTX | Health | BioPrd | Biological Products, (No Diag | Gaspar Bobby | X0 | DO | CEO | P | 11 | 0.7390 | 0 | 15 | 4 | 370 | D | | | | | | | | | | | | | | |
4/4/22 16:15 | 4/1/22 | ORTX | Health | BioPrd | Biological Products, (No Diag | Thomas Frank E | X0 | O | See Rema | P | 7 | 0.7474 | 0 | 10 | 24 | 52 | D | | | | | | | | | | | | | | |
2/10/21 13:39 | 2/5/21 | ORTX | Health | BioPrd | Biological Products, (No Diag | Fmr LLC | MA | TH | See Rema | S | -14,278 | 6.98 | 0 | -2,046 | -17 | 10,199 | I | | | | | | | | | | | | | | |
2/1/21 16:15 | 1/29/21 | ORTX | Health | BioPrd | Biological Products, (No Diag | Thomas Frank E | X0 | O | See Rema | M.d | 24 | 2.44 | 0 | 10 | 31 | 42 | D | | | | | | | | | | | | | | |
11/6/20 16:32 | 8/10/20 | ORTX | Health | BioPrd | Biological Products, (No Diag | Ra Capital Management, L.P. | MA | T | | P.m | 3,563 | 4.63 | 0 | 769 | 8 | 9,881 | I | | | | | | | | | | | | | | |
6/15/20 17:03 | 6/11/20 | ORTX | Health | BioPrd | Biological Products, (No Diag | Thomas Frank E | X0 | O | See Rema | M.d | 24 | 2.44 | 0 | 10 | 66 | 25 | D | | | | | | | | | | | | | | |
3/4/20 17:06 | 3/2/20 | ORTX | Health | BioPrd | Biological Products, (No Diag | Gaspar Bobby | X0 | DO | See Rema | M.d | 0 | 0.0001 | 0 | 5 | 1 | 352 | D | | | | | | | | | | | | | | |
3/4/20 17:06 | 3/2/20 | ORTX | Health | BioPrd | Biological Products, (No Diag | Gaspar Bobby | X0 | DO | See Rema | S.d | -64 | 13.00 | 0 | -5 | -1 | 352 | D | | | | | | | | | | | | | | |
1/6/20 17:34 | 1/2/20 | ORTX | Health | BioPrd | Biological Products, (No Diag | Fmr LLC | MA | TH | See Rema | S | -383 | 13.46 | 0 | -28 | 0 | 12,245 | I | | | | | | | | | | | | | | |